Clinical application of growth factors and cytokines in wound healing

Wound Repair and Regeneration

Volumn 22, Issue 5, 2014, Pages 569-578

  Barrientos, Stephan ^a   Brem, Harold ^a   Stojadinovic, Olivera ^b   Tomic Canic, Marjana ^b  

^a STONY BROOK UNIVERSITY   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; FIBROBLAST GROWTH FACTOR 2; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; PROTEINASE; VASCULOTROPIN;

ARTICLE; DEBRIDEMENT; HUMAN; MULTICENTER STUDY (TOPIC); NONHUMAN; OFF LABEL DRUG USE; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); WOUND HEALING;

EID: 85007210857     PISSN: 10671927     EISSN: 1524475X     Source Type: Journal    
DOI: 10.1111/wrr.12205     Document Type: Article

References (125)

1. Trengrove N, Bielefeldt-Ohmann H, Stacey M. Mitogenic activity and cytokine levels in non-healing and healing chronic leg ulcers. Wound Repair Regen 2000; 8: 13–25.
2. Brown L, Yeo K, Berse B, Yeo T, Senger D, Vorak H, et al. Expression of vascular permeability factor (vascular endothelial growth factor) on epidermal keratinocytes during wound healing. J Exp Med 1992; 176: 1375–1379.
3. Powers C, McLeskey S, Wellstein A. Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer 2000; 7: 165–167.
4. Center for Disease Control and Prevention. National diabetes fact sheet, 2011. Available at: http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf (accessed February 19, 2013).
5. Brown G. Long-term outcomes of full thickness pressure ulcers: healing and mortality. Ostomy Wound Manage 2003; 49: 42–50.
6. Brem H, Maggi J, Nierman D, Rolnitzky L, Bell D, Rennert R, et al. High cost of stage IV pressure ulcers. Am J Surg 2010; 200: 473–477.
7. Russo A, Steiner C, Spector W. Hospitalizations related to pressure ulcers among adults 18 years and older, 2006. Rockville: Agency for healthcare Research and Quality, 2008. http://www.hcup-us.ahrq.gov/reports/statbriefs/sb64.jsp.
8. Valensi P, Paries J, Lormeau B, Attia S, Attiali J. Influence of nutrients on cardiac autonomic function I nondiabetic overweight subjects. Metabolism 2005; 54: 1290–1296.
9. Finnerty C, Jeschke M, Herndon D, Gamelli R, Gibran N, Klein M. Temporal cytokine profiles in severely burned patients: a comparison of adults and children. Mol Med 2008; 14: 553–560.
10. Finnerty C, Przkora R, Herndon D, Jeschke M. Cytokine expression profile over time in burned mice. Cytokine 2009; 45: 20–25.
11. Rubbia-Brandt L, Sappino A, Gabbiani G. Locally applied GM-CSF induces the accumulation of alpha-smooth muscle actin containing myofibroblasts. Virchows Arch B Cell Pathol Incl Mol Pathol 1991; 60: 73–82.
12. Yomen A, Cakir B, Culer S, Azal O, Corakci A. Effects of granulocyte colony stimulating factor in the treatment of diabetic foot infection. J Invest Dermatol 1996; 107: 404–411.
13. Smith C, Allen M, Groves R, Barker J. Effect of granulocyte macrophage-colony stimulating factor on Langerhans cells in normal and healthy atopic subjects. Br J Dermatol 1998; 139: 239–246.
14. Mann A, Breuhahan K, Schirmacher P, Blessing M. Keratinocyte-derived granulocyte-macrophage colony stimulating factor accelerates wound healing: stimulation of keratinocyte proliferation, granulation tissue formation and vascularization. J Invest Dermatol 2001; 117: 1382–1390.
15. Kaplan G, Walsh G, Guido L, Meyn R, Abalos R. Novel responses of human skin to intradermal recombinant granulocyte/ macrophage-colony-stimulating factor: Langerhans cell recruitment, keratinocyte growth, and enhanced wound healing. J Exp Med 1992; 175: 1717–1728.
16. Schriber J, Negrin R, Chao N, Long G, Horning S, Blume K. The efficacy of granulocyte colony-stimulating factor following autologous bone marrow transplantation for non-Hodgkin's lymphoma with monoclonal antibody purged bone marrow. Leukemia 1993; 7: 1491–1495.
17. Fanin R, Baccarani M. Granulocyte-macrophage colony stimulating factor in acute non-lymphocytic leukemia. J Intern Med 1994; 236: 487–493.
18. Carral A, de la Rubia J, Martin G, Martinex J, Sanz G, Jarque I. Factors influencing hematopoietic recovery after antilogous blood stem cell transplantation in patients with acute myeloblastic leukemia and with non-myeloid malignancies. Bone Marrow Transplant 2002; 29: 825–832.
19. Visani G, Tosi P, Gamberi B, Cenacchi A, Mazzanti P, Stabilini C. Accelerated hemopoietic recovery after chemotherapy and autologous bone marrow transplantation in hematological malignancies using recombinant GM-CSF; preliminary results obtained in14 cases. Hematologica 1990; 75: 551–554.
20. Gorin N, Coieffier B, Haat M, Fouillard L, Kuentz M, Flesch M. Recombinant human granulocyte-macrophage colony stimulating factor after high dose chemotherapy and autologous bone marrow transplantation with unpurged and purged marrow in non-Hodgkin's lymphoma: A double blind placebo controlled trial. Blood 1992; 80: 1149–1157.
21. Jorgensen L, Argren M, Madsen S, Kallehave F, Vossoughi F, Rasmussen A. Dose-dependent impairment of collagen deposition of topical granulocyte macrophage colony stimulating factor in human experimental wounds. Ann Surg 2002; 236: 684–692.
22. Fang Y, Gong S, Xu Y, Hambly B, Bao S. Impaired cutaneous wound healing in granulocyte/macrophage colony stimulating factor knockout mice. Br J Dermatol 2007; 157: 458–465.
23. Fang Y, Shen J, Yao M, Beagley K, Hambly B, Bao S. Granulocyte-macrophage colony stimulating factor enhances wound healing in diabetes via up-regulation of proinflammatory cytokines. Br J Dermatol 2010; 162: 478–486.
24. Gulcelik M, Dinc S, Dinc M, Yenidogan E, Ustun H, Renda N. Local granulocyte-macrophage colony stimulating factor improves incisional wound healing in adriamycin-treated rats. Surg Today 2006; 36: 47–51.
25. Sugiyama K, Ishii G, Ochiai A, Esumi H. Improvement of the breaking strength of wound by combined treatment with recombinant human G-CSF, recombinant human M-CSF, and TGF-beta1 receptor kinase inhibitor in rate skin. Cancer Sci 2008; 99: 1021–1028.
26. Ergun S, Kyran B, Su O, Bilgic B, Yssever H, Kucuk M. Effects of granulocyte macrophage colony stimulating factor on random flap healing and immune profile in rates with impaired wound healing by glucocorticoids. Ann Plast Surg 2004; 52: 80–88.
27. Gamelli R, He L, Liu H. Recombinant human granulocyte colony-stimulating factor treatment improves macrophage suppression of granulocyte and macrophage growth after burn and burn wound infection. J Trauma 1995; 39: 1141–1146.
28. Memisoglu E, Oner F, Ayhan A, Basaran I, Hincal A. In vivo evaluation for rhGM-CSF wound-healing efficacy in topical vehicles. Pharm Dev Technol 1997; 2: 171–180.
29. Bayer Pharmacuticals. Leukine, 2009. http://www.pharma.bayer.com/scripts/pages/en/news_room/news_room/news_room79.php (accessed May 30, 2013).
30. Da Costa R, Jesus F, Aniceto C, Mendes M. Randomized, double-blind, placebo-controlled, dose ranging study of granulocyte-macrophage colony stimulating factor in patients with chronic venous leg ulcers. Wound Repair Regen 1999; 7: 17–25.
31. Da Costa R, Jesus F, Aniceto C, Mendes M. Double-blind randomized placebo-controlled trial of the use of granulocyte-macrophage colony stimulating factor in chronic leg ulcers. Am J Surg 1997; 173: 165–168.
32. Jaschke E, Zabernigg A, Gattringer C. Recombinant human granulocyte-macrophage colony-stimulating factor applied locally in low does enhances healing and prevents recurrence of chronic venous ulcers. Int J Dermatol 1999; 38: 380–386.
33. Robson M, Hill D, Smith P, Wang X, Meyer-Siegler K, Ko F. Sequential cytokine therapy for pressure ulcers: clinical and mechanistic response. Ann Surg 2000; 231: 600–611.
34. El Saghir N, Bizri A, Shab N, Husami T, Salem Z, Shameseddine A. Pressure ulcer accelerated healing with local injections of granulocyte macrophage-colony stimulating factor. J Infect 1997; 35: 179–182.
35. Gough A, Clapperton M, Rolando N, Foster A, Philpott-Howard J, Edmonds M. Randomized placebo-controlled trial of granulocyte-colony stimulating factor in diabetic foot infections. Lancet 1997; 350: 855–859.
36. West N. Systemic antimicrobial treatment of foot infections in diabetic patients. Am J Health Syst Pharm 1995; 52: 1199–1207.
37. Bianchi L, Ginerbri A, Hagman J, Francesconi F, Carboni I, Chimenti S. Local treatment of chronic cutaneous leg ulcers with recombinant human granulocyte-macrophage colony stimulating factor. J Eur Acad Dermatol Venereol 2002; 16: 595–598.
38. Zhang L, Chen J, Han C. A multicenter clinical trial of recombinant human GM-CSF hydrogel for the treatment of deep 2nd degree burns. Wound Repair Regen 2009; 17: 685–689.
39. Wang Z, Zhang Q, Liao Z, Han C, Lv G, Luo C. Effect of recombinant human granulocyte-macrophage colony stimulating factor on wound healing in patients with deep partial thickness burn. Zhonghua Shao Shang Za Zhi 2008; 24: 107–110.
40. Cianfarani F, Tommasi R, Failla C, Viviano M, Annessi G, Papi M. Granulocyte/ macrophage colony-stimulating factor treatment of human chronic ulcers promotes angiogenesis associated with de novo vascular endothelial growth factor transcription in the ulcer bed. Br J Dermatol 2006; 154: 34–41.
41. Kudlak K, Demuro J, Hanna A, Brem H. Acute lung injury following the use of granulocyte-macrophage colony-stimulating factor. Int J Crit Illn Inj Sci 2013; 3: 279–281.
42. Vogt P, Lehnhardt M, Wagner D, Jansen V, Krieg M, Steinau H. Determination of endogenous growth factors in human wound fluid: temporal presence and profiles of secretion. Plast Reconstr Surg 1998; 102: 117–123.
43. Heldin C, Westmark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 1999; 79: 1283–1316.
44. Lindahl P, Johansson B, Leveen P, Betsholtz C. pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 1997; 277: 242–245.
45. Sundberg C, Branting M, Gerdin B, Rubin K. Tumor cell and connective tissue cell interaction in human colorectal adenocarcinoma. Transfer of platelet-derived growth factor-AB/BB to stromal cells. Am J Pathol 1997; 151: 479–492.
46. Rabhi-Sabile S, Pidard D, Lawler JJ, Renesto P, Chignard M, Legrand C. Proteolysis of thrombospondin during cathepsin-G-induced platelet aggregation: functional role of the 165 kDa carboxy-terminal fragment. FEBS Lett 1996; 386: 82–86.
47. Krishnaswami S, Ly Q, Rothman V, Tuszynski G. Thromospondin-1 promotes proliferative healing through stabilization of PDGF. J Surg Res 2002; 107: 124–130.
48. Lin H, Chen B, Sun W, Zhao W, Zhao Y, Dai J. The effect of collagen-targeting platelet derived growth factor on cellularization and vascularization of collagen scaffolds. Biomaterials 2006; 27: 5708–5714.
49. Rhee S, Grinnel F. P21-activated kinase 1: convergence point in PDGF- and LPA-stimulated collagen matrix contraction by human fibroblasts. J Cell Biol 2006; 172: 423–432.
50. Robson M. The role of growth factors in the healing of chronic wounds. Wound Repair Regen 1997; 5: 12–17.
51. Mast B, Schultz G. Interactions of cytokines, growth factors, proteases in acute and chronic wounds. Wound Repair Regen 1996; 4: 411–420.
52. Food and Drug Administration. Regranex, 2008 http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM142821.pdf (accessed May 30, 2013).
53. D'Hemecourt P, Smiell J, Karim M. Sodium carboxymethylcellulose aquesous-based gel vs. becapleermin gel in patients with nonhealing lower extremity diabetic ulcers. Wounds 1998; 10: 69–75.
54. Steed D, The Diabetic Ulcer Study Group. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. J Vasc Surg 1995; 21: 71–81.
55. Wieman T, Smiell J, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers: a phase III, randomized placebo-controlled, double-blind study. Diabetes Care 1998; 21: 822–827.
56. Krupski W, Reilly L, Perez S, Moss K, Crombleholme P, Rapp J. A prospective randomized trial of autologous platelet-derived wound healing factors for treatment of chronic nonhealing wounds: a preliminary report. J Vasc Surg 1991; 14: 526–532.
57. Smiell J, Wiemann T, Steed D, Perry B, Sampson A, Schawb B. Efficacy and safety of becaplermin in patients with non healing lower extremity diabetic ulcers: a combined analysis of four randomized studies. Wound Repair Regen 1999; 7: 335–345.
58. Margolis D, Bartus C, Hoffstad O, Malay S, Berlin J. Effectiveness of recombinant human platelet–derived growth factor for the treatment of diabetic neuropathic foot ulcers. Wound Repair Regen 2005; 13: 5531–5536.
59. Robson M, Phillips L, Thompson A. A recombinant human platelet derived growth factor- BB in the treatment of chronic pressure ulcers. Ann Plast Surg 1992; 29: 193–201.
60. Rees R, Robson M, Smiell J, Perry B, The pressure ulcer study group. Becaplermin gel in the treatment of pressure ulcers: a phase II randomized, double blind placebo controlled study. Wound Repair Regen 1999; 7: 141–147.
61. Mustoe T, Cutler N, Allman R. A phase II study to evaluate recombinant platelet derived growth factor BB inthe treatment of stage 3 and 4 pressure ulcers. Arch Surg 1994; 129: 213–219.
62. Margolis D, Morris L, Papadopoulos M, Weinberg L, Filip J, Lang S, et al. Phase I study of H5.020CMV.PDGF-B to treat Venous leg ulcer disease. Mol Ther 2009; 17: 1822–1829.
63. Crombleholme T. Adenoviral-mediated gene transfer in wound healing. Wound Repair Regen 2000; 8: 460–472.
64. Liechty K, Sablich T, Adzick N, Crombleholme T. Recombinant adenoviral mediated gene transfer in ischemic impaired wound healing. Wound Repair Regen 1999; 7: 148–153.
65. Sylvester K, Nesbit M, Radu A, Herlyn M, Adzick N, Crombleholme T. Adenoviral-mediated gene transfer in wound healing; acute inflammatory response in human skin in the SCID mouse model. Wound Repair Regen 2000; 8: 36–44.
66. Gruss C, Satyamoorthy L, Berking C, Lininger K, Nesbit M, Schaider H. Stroma formation and angiogenesis by overexpression of growth factors, cytokines, and proteoltic enzymes in human skin grafted to SCID mice. J Invest Dermatol 2003; 120: 683–692.
67. Barrientos S, Stojadinovic O, Golinko M, Brem H, Tomic-Canic M. Growth factors and cytokines in wound healing. Wound Repair Regen 2008; 16: 585–601.
68. Bennett S, Friffith G, Schor A, Leese G, Schor S. Growth factors in the treatment of diabetic foot ulcers. Br J Surg 2003; 90: 133–146.
69. Wu L, Pierce G, Galiano R, Mustoe T. Keratinocyte growth factor induces granulation tissue in ischemic dermal wounds. Importance of epithelial-mesenchymal cell interactions. Arch Surg 1996; 131: 660–666.
70. Ceccarelli S, Cardinali G, Aspite N, Picardo M, Marchese C, Torrisi M, et al. Cortactin involvement in the keratinocyte growth factor and fibroblast growth factor 10 promotion of migration and cortical actin assembly in human keratinocytes. Exp Cell Res 2007; 313: 1758–1777.
71. Gallucci R, Sloan D, Heck J, Murray A, O'dell S. Interleukin 6 indirectly induces keratinocyte migration. J Invest Dermatol 2004; 122: 764–772.
72. Sato M, Sawamura D, Ina S, Yagushi T, Hanada K, Hashimoto I. In vivo introduction of the interleukin 6 gene into human keratinocytes: induction of epidermal proliferation by the fully spliced form of interleukin 6, but not by the alternatively spliced form. Arch Dermatol Res 1999; 291: 400–404.
73. Powers C, McLeskey S, Wellstein A. Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer 2000; 7: 165–197.
74. Sogabe Y, Abe M, Yokoyama Y, Ishikawa O. Basic fibroblast growth factor stimulates human keratinocyte motility by Rac activation. Wound Repair Regen 2006; 14: 457–462.
75. Grellner W, Georg T, Wilske J. Quantitative analysis of proinflammatory cytokines (IL-1beta, IL-6, TNF alpha) in human skin wounds. Forensic Sci Int 2000; 113: 251–264.
76. Di Vita G, Patti R, D'Agostino P, Caruso G, Arcara M, Buscemi S, et al. Cytokines and growth factors in wound drainage fluid from patients undergoing incisional hernia repair. Wound Repair Regen 2006; 14: 259–264.
77. Sasaki T. The effects of basic fibroblast growth factor and doxorubicin on cultured human skin fibroblasts: relevance to wound healing. J Dermatol 1992; 19: 664–666.
78. Robson M, Phillips L, Lawrence W, Bishop J, Youngerman J, Hayward P, et al. The safety and effect of topically applied recombinant basic fibroblast growth factor on the healing of chronic pressure sores. Ann Surg 1992; 216: 401–408.
79. Ohura T, Nakajo T, Moriguchi T, Oka H, Tachi M, Ohura N, et al. Clinical efficacy of basic fibroblast growth factor on pressure ulcers: case-control pairing study using a new evaluation method. Wound Repair Regen 2011; 19: 542–550.
80. Payne W, Ochs D, Meltzer D, Hill D, Mannari R, Robson L, et al. Long-term outcome study of growth factor-treated pressure ulcers. Am J Surg 2001; 181: 81–86.
81. Richard J, Parer-Richard C, Daures J, Clouet S, Vannereau D, Bringer J, et al. Effect of topical basic fibroblast growth factor on the healing of chronic diabetic neuropathic ulcer of the foot. Diabetes Care 1995; 18: 64–69.
82. Uchi H, Igarashi A, Urabe K, Koga T, Nakayama J, Kawamori R, et al. Clinical Efficacy of basic fibroblast growth factor (bFGF) for diabetic ulcers. Eur J Dermatol 2009; 19: 461–468.
83. Fu X, Shen Z, Chen Y, Xie K, Guo Z, Zhang M, et al. Randomized placebo-controlled trial of use of topical recombinant bovine basic fibroblast growth factor for second degree burns. Lancet 1998; 352: 1661–1664.
84. Nie K, Li P, Zeng X, Sun G, Jin W, Wei Z, et al. Clinical observation of basic fibroblast growth factor combined with topical oxygen therapy in enhancing burn wound healing. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 2010; 24: 643–646.
85. Guo H, Xu G, Wang B, Qui M, Zhu Z, Ke J, et al. Effects of perforated bovine amnion combined with recombinant bovine basic fibroblast growth factor on degree II burn wounds: a comparison with imperforated bovine amnion and Vaseline gauze dressing. J Clin Rehab Tissue Eng Res 2009; 13: 10193–10196.
86. Chang F, Wu H, Zhang Y, Zhang W, Yang CW, Xia ZF, et al. Gene gun-delivered human basic fibroblast growth factor gene facilitates the healing of deep partial thickness burn wounds. J Clin Rehab Tissue Eng Res 2009; 13: 4611–4615.
87. Sivamani R, Garcia M, Isseroff R. Wound re-epithelialization: modulating keratinocyte migration in wound healing. Front Biosci 2007; 12: 2849–2868.
88. Niu J, Chang Z, Peng B, Xia Q, Lu W, Huang P, et al. Keratinocyte growth factor/ fibroblast growth factor-7-regulated cell migration and invasion through activation of NF-kappaB transcription factors. J Biol Chem 2007; 282: 6001–6011.
89. Robson M, Phillips T, Falanga V, Odenheimer D, Parish L, Jensen J, et al. Randomized trial of topically applied repifermin (recombinant human keratinocyte growth factor-2) to accelerate wound healing in venous ulcers. Wound Repair Regen 2001; 9: 347–352.
90. Robson M, Hanfnt J, Garner W, Jenson J, Serena T, Payne W, et al. Healing of chronic venous ulcers is not enhanced by the addition of topical repifermin (KGF-2) to standardized care. J Appl Res 2004; 4: 302–311.
91. Saaristo A, Tammela T, Farkkila A, Karkkainen M, Suominen E, Yla-Herttuala S, et al. Vascular endothelial growth factor-C accelerates diabetic wound healing. Am J Pathol 2006; 169: 1080–1087.
92. Yebra M, Parry G, Stromblad S, Mackman N, Rosenberg S, Mueller B, et al. Requirement of receptor-bound urokinase-type plasminogen activator for integrin alphavbeta5-directed cell migration. J Biol Chem 1996; 271: 29393–29399.
93. Suzuma K, Takagi H, Otani A, Honda Y. Hypoxia and vascular endothelial growth factor stimulate angiogenic integrin expression in bovine retinal microvascular endothelial cells. Invest Ophthalmol Vis Sci 1998; 39: 1028–1035.
94. Senger D, Ledbetter S, Claffey K, Papadopoulous-Sergiou A, Peruzzi C, Detmar M. Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanism involving the alphavbeta3 integrin, osteopontin, and thrombin. Am J Pathol 1996; 149: 293–305.
95. Morbidelli L, Chang C, Douglas J, Granger H, Ledda F, Ziche M. Nitric oxide mediates mitogenic effect of VEGF on coronary venular endothelium. Am J Physiol 1996; 270 (1 Pt 2): H411–415.
96. Pepper M, Ferrara N, Orci L, Montesano R. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun 1992; 189: 824–831.
97. Goto F, Goto K, Windel K, Folkman J. Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels. Lab Invest 1993; 69: 508–517.
98. Wantanabe Y, Lee S, Detmar M, Ajioka I, Dvorak H. Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) delays and induces escape from senescence in human dermal microvascular endothelial cells. Oncogene 1997; 14: 2025–2032.
99. Nissen N, Polverini P, Koch A, Volin M, Gamelli R, DiPietro L. Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing. Am J Pathol 1998; 152: 1445–1452.
100. Banks R, Forbes M, Kinsey S, Stanley A, Ingham E, Wlaters C, et al. Release of angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer 1998; 77: 956–964.
101. Gaudry M, Bregerie O, Andrieu V, El Benna J, Pocidalo M, Hakim J. Intracellular pool of vascular endothelial growth factor in human neutrophils. Blood 1997; 90: 4153–4161.
102. Berse B, Brown L, Van de Water L, Dvorak H, Senger D. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages and tumors. Mol Biol Cell 1992; 3: 211–220.
103. Jazwa A, Loboda A, Golda S, Cisowski J, Szelag M, Zagorska A, et al. Effect of heme and heme oxygenase-1 on vascular endothelial growth factor synthesis and angiogenic potency of human keratinocytes. Free Radic Biol Med 2006; 40: 1250–1263.
104. Walder C, Errett C, Unting S, Lindquist P, Ogez J, Heinsohn H, et al. Vascular endothelial growth factor augments muscle blood flow and function in a rabbit model of chronic hindlimb ischemia. J Cardiovasc Pharmacol 1996; 27: 91–98.
105. Bauters C, Asahara T, Zheng L, Takeshita S, Bunting S, Ferrara N, et al. Site-specific therapeutic angiogenesis after systemic administration of vascular endothelial growth factor. J Vasc Surg 1995; 21: 314–324, discussion 324–25.
106. Bauters C, Asahara T, Zheng L, Takeshita S, Bunting S, Ferarra N, et al. Physiological assessment of augmented vascularity induced by VEGF in ischemic rabbit hindlimb. Am J Physiol 1994; 267 (4 Pt 2): 1263–1271.
107. Takeshita S, Pu L, Stein L, Sniderman A, Bunting S, Ferrara N, et al. Intramuscular administration of vascular endothelial growth factor induces dose-dependent collateral artery augmentation in a rabbit model of chronic limb ischemia. Circulation 1995; 90 (5 Pt2): 228–234.
108. Takeshita S, Wheng L, Brogi E, Kearney M, Pu L, Bunting S, et al. Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest 1994; 93: 662–670.
109. Galiano R, Tepper O, Pelo C, Bhatt K, Callaghan M, Bastidas N, et al. Topical endothelial growth factor accelerates diabetic wound healing through increased angiogenesis and by mobilizing and recruiting bone marrow-derived cells. Am J Pathol 2004; 164: 1935–1947.
110. Nagy J, Vasile E, Geng D, Sundberg C, Brown L, Detmar M, et al. Vascular permeability factor/ vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. J Exp Med 2002; 196: 1497–1506.
111. Carmeliet P. VEGF gene therapy: stimulating angiogenesis or angioma-genesis? Nat Med 2000; 6: 1102–1103.
112. Kusumanto Y, van Weel V, Mulder N, Smit A, van den Dungen J, Hooymans J, et al. Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double blind randomized trial. Hum Gene Ther 2006; 17: 683–691.
113. Hanft J, Pollak R, Barbul A, van Gils C, Kwon P, Gray S, et al. Phase I trial on the safety of topical rhVEGF on chronic neuropathic diabetic foot ulcers. J Wound Care 2008; 17: 30–32, 34–7.
114. Chen SM, Ward SI, Olutoye OO, Diegelmann RF, Kelman Cohen I. Ability of chronic wound fluids to degrade peptide growth factors is associated with increased levels of elastase activity and diminished levels of proteinase inhibitors. Wound Repair Regen 1997; 5: 23–32.
115. Wysocki AB, Staiane-Coico L, Grinnell F. Wound fluid from chronic leg ulcers contain elevated levels of metalloproteinases MMP-2 and MMP-9. J Invest Dermatol 1993; 101: 64–68.
116. Yager DR, Zhang LY, Liang HX, Diegelmann RF, Cohen IK. Wound fluids from human pressure ulcers contain elevated matrix metalloproteinase levels and activity compared to surgical wounds. J Invest Dermatol 1996; 107: 743–748.
117. Bullen EC, Longaker MT, Updike DL, Benton R, Ladin D, Hou Z, et al. Tissue inhibitor of metalloproteinases-1 is decreased and activated gelatinases are increased in chronic wounds. J Invest Dermatol 1995; 104: 236–240.
118. Brem H, Stojadinovic O, Diegelmann R, Entero H, Lee B, Pastar I, et al. Molecular markers in patients with chronic wounds to guide surgical debridement. Mol Med 2007; 13: 30–39.
119. Steed D, Donohoe D, Webster M, Lindsley L. Effect of extensive debridement and treatment on the healing of diabetic foot ulcers. Diabetic Ulcer Study Group. J Am Coll Surg 1996; 183: 61–64.
120. Hess C, Kirsner R. Orchestrating wound healing: assessing and preparing the wound bed. Adv Skin Wound Care 2003; 16: 246–257.
121. Saap L, Falanga V. Debridement performance index and its correlation with complete closure of diabetic foot ulcers. Wound Repair Regen 2002; 10: 354–359.
122. Schiffman J, Golinko M, Yan A, Flattau A, Tomic-Canic M, Brem H. Operative debridement of pressure ulcers. World J Surg 2009; 33: 1396–1402.
123. Golinko M, Joffe R, Maggi J, Cox D, Chandrasekaran E, Tomic-Canic M, et al. Operative debridement of diabetic foot ulcers. J Am Coll Surg 2008; 207: e1–5.
124. Pastar I, Stojadinovic O, Krzyanowska A, Barrientos S, Stuelten C, Zimmerman K, et al. Attenuation of the transforming growth factor beta-signaling pathway in chronic venous ulcers. Mol Med 2010; 16: 92–101.
125. Brem H, Golinko M, Stojadinovic O, Kodra A, Diegelmann R, Vukelic S, et al. Primary cultured fibroblasts derived from patients with chronic wounds: a methodology to produce human cell lines and test putative growth factor therapy such as GMCSF. J Transl Med 2008; 1: 75–84.